Evidence map›Paper›PMID 40026293›Full record

ArticleThe Journal of pathology2025

Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.

Max Ak Rätze, Lotte Nfl Enserink, Noboru Ishiyama, Sven van Kempen, Christina Hj Veltman, Isaac J Nijman, Wisse E Haakma, Carlos Caldas, René Bernards, Paul J van Diest and 3 more

Abstract read
In one paragraph

Article in The Journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026
    Review
  2. Spatial transcriptomics reveals tumor microenvironment-driven subtypes of invasive lobular carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Max Ak RätzeDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Lotte Nfl EnserinkDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Noboru IshiyamaLaunchpad Therapeutics, Inc, Cambridge, MA, USA.
Sven van KempenDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Christina Hj VeltmanDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Isaac J NijmanCenter for Molecular Medicine, Cancer Genomics Netherlands, Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
Wisse E HaakmaDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Carlos CaldasCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
René BernardsDivision of Molecular Carcinogenesis, Center for Biomedical Genetics and Cancer Genomics Centre, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-8677-3423
Paul J van DiestDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0003-0658-2745
Matthias ChristgenInstitute of Pathology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-0891-7839
Thijs KoormanDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-6064-3353
Patrick Wb DerksenDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0003-0732-7762

Funding

Breast Cancer Now 2018NovPCC1297European Cooperation in Science and Technology CA19138Horizon 2020 Framework Programme 731957KWF Kankerbestrijding 10456Nederlandse Organisatie voor Wetenschappelijk Onderzoek 184.034.019
6 · The paper itself

Abstract

Afadin is a multimodal scaffolding protein with essential functions in cell-cell adhesion. Although its loss of expression has been linked to breast cancer invasion and metastasis, the underlying mechanisms driving tumour progression upon mutational Afadin (AFDN) loss in breast cancers remains unclear. In the current study we identified a somatic frameshift AFDN mutation (p.Lys630fs) in an invasive breast cancer sample that coincides with loss of Afadin protein expression. Functional studies in E-cadherin-expressing breast cancer cells show that Afadin loss leads to immature and aberrant adherens junction (AJ) formation. The lack of AJ maturation results in a noncohesive cellular phenotype accompanied by Actomyosin-dependent anoikis resistance, which are classical progression hallmarks of single-cell breast cancer invasion. Reconstitution experiments using Afadin truncates show that proper F-actin organisation and epithelial cell-cell adhesion critically depend on the Coiled-Coil domain of Afadin but not on the designated C-terminal F-actin binding domain. Mouse xenograft experiments based on cell lines and primary patient-derived breast cancer organoids demonstrate that Afadin loss induces single-cell lobular-type invasion phenotypes and overt dissemination to the lungs and the peritoneum. In short, Afadin is a metastasis suppressor for breast cancer through stabilisation and maturation of a mechanical E-cadherin to F-actin outside-in link. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

ActinsAntigens, CDBreast NeoplasmsCadherinsMicrofilament ProteinsAdherens JunctionsAnimalsAnoikisCell AdhesionCell Line, TumorFemaleHumansMiceMutationNeoplasm InvasivenessNeoplasm MetastasisActinsafadinAntigens, CDCadherinsCDH1 protein, humanMicrofilament Proteinsadherens junctionAfadinE‐cadherinmetastatic breast cancer

Identifiers

PMID40026293
PMCPMC11985701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.